about
New and emerging drug molecules against obesity.Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug.Pattern of Adverse Drug Reactions Reported with Cardiovascular Drugs in a Tertiary Care Teaching Hospital.Evaluation of Endothelial and Platelet Derived Microparticles in Patients with Acute Coronary Syndrome.GDF 15--A Novel Biomarker in the Offing for Heart Failure.Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.Novel drug targets in clinical development for heart failure.Looking into the crystal ball-upcoming drugs for dyslipidemia.Riociguat: Something new in pulmonary hypertension therapeutics?A peek into the drug development scenario of endometriosis - A systematic review.End points in heart failure-are we doing it right?Molecular analysis of the LDLR gene in coronary artery disease patients from the Indian population.Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study.Do ANGPTL-4 and galectin-3 reflect the severity of coronary artery disease?Authors reply to "No, we are not-we keep forgetting the right ventricle".Effect of metformin on exercise capacity in metabolic syndrome.Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine.Prognostic role of soluble ST2 in acute coronary syndrome with diabetesNovel approaches in the treatment of diabetic cardiomyopathy
P50
Q30353872-CFE4EA39-AAC4-4312-8260-A66FDA4CC98EQ35286926-1FBF0F77-8A77-4BBC-9F46-44DFCCC7F69CQ36313485-6EFD2C2F-3DC5-4243-A142-E0E5F2E78801Q36343484-3D4B39CE-7B5F-4F39-B531-A980D50F5A73Q36476672-A6770F0F-4D3D-4C9E-875E-EFCD5F3EF331Q36728674-9B6109DA-30D7-49D9-BA29-09B692A16496Q36776537-B3B38021-BB47-4F4D-BAAA-D58B73166928Q38202895-AD5D4CBC-7EDA-4FDA-886A-D6588DAA2C33Q38235611-04AEE929-4076-4C24-B0C6-799B3007BBAFQ38364678-0F93BDCD-3C4A-410A-BF0A-983A3D4CDA40Q38730691-35E6F0DA-89AC-4E64-AFC6-53BC42263F00Q38915710-D02170AD-381A-478A-87D5-ECC2B7414A97Q40880339-F30861BA-1935-4ABB-9136-A38E978FCC9BQ41151739-9B418DF7-700F-48A9-9135-E6C8397B9EEBQ47969856-4A91EA05-A14A-4D0E-8159-0E275CC611DFQ50091699-7DDE6C9F-6D77-438B-8715-670079876C00Q50850190-D8E08B68-33AD-4AD1-89E5-712E493E31F3Q54306979-7D5742D9-76F1-4A26-BD30-4A5D5FA46A06Q57163517-DD09852D-A187-46EC-82EB-38116383B897Q91006633-8F0F7364-29A7-46AB-9DEA-23F171B2129F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Melvin George
@ast
Melvin George
@en
Melvin George
@es
Melvin George
@nl
type
label
Melvin George
@ast
Melvin George
@en
Melvin George
@es
Melvin George
@nl
prefLabel
Melvin George
@ast
Melvin George
@en
Melvin George
@es
Melvin George
@nl
P106
P1153
55350370200
P21
P31
P496
0000-0001-7101-8513